Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | GLS | O94925 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29707271 | 1.00 | ALDH1A1 (0.54) | ALDH1A1TDP1L3MBTL1MAPTRAB9A | |
| SCHEMBL16068174 | 0.95 | TDP1 (0.53) | ALDH1A1TDP1L3MBTL1MAPTRAB9A | |
| SCHEMBL30041074 | 0.95 | TDP1 (0.53) | ALDH1A1TDP1L3MBTL1MAPTRAB9A | |
| SCHEMBL13884659 | 0.93 | TDP1 (0.55) | ALDH1A1TDP1L3MBTL1CYP1A2CYP2C19 | |
| SCHEMBL20595306 | 0.93 | TDP1 (0.55) | ALDH1A1TDP1L3MBTL1CYP1A2CYP2C19 | |
| SCHEMBL17872139 | 0.93 | TDP1 (0.55) | ALDH1A1TDP1L3MBTL1CYP1A2CYP2C19 | |
| SCHEMBL30999497 | 0.89 | GLS (0.52) | ALDH1A1TDP1L3MBTL1MAPTRAB9A | |
| SCHEMBL13754582 | 0.89 | GLS (0.52) | ALDH1A1TDP1L3MBTL1MAPTRAB9A | |
| SCHEMBL14499669 | 0.81 | HPGD (0.50) | ALDH1A1TDP1L3MBTL1MAPTRAB9A | |
| SCHEMBL12890373 | 0.80 | TDP1 (0.54) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114671816-B | Preparation method of axial chiral aryl triazole compound | 浙江大学 | 2023-11-17 | — | — | CN | disclosed |
| US-20220324770-A1 | NITRIFICATION INHIBITORS | THE UNIVERSITY OF MELBOURNE (AU) | 2022-10-13 | — | — | US | disclosed |
| EP-4025564-A1 | NITRIFICATION INHIBITORS | The University of Melbourne (AU) | 2022-07-13 | — | — | EP | disclosed |
| CN-114616227-A | Nitrification inhibitors | 墨尔本大学 | 2022-06-10 | — | — | CN | disclosed |
| WO-2021042169-A1 | NITRIFICATION INHIBITORS | THE UNIVERSITY OF MELBOURNE (AU) | 2021-03-11 | — | — | WO | disclosed |
| EP-2630494-B1 | METHOD FOR FUNCTIONALISING SURFACES FOR ANALYTE DETECTION | CENTRE NAT RECH SCIENT (FR) | 2020-03-18 | — | — | EP | disclosed |
| EP-2630494-B1 | METHOD FOR FUNCTIONALISING SURFACES FOR ANALYTE DETECTION | CENTRE NAT RECH SCIENT (FR) | 2020-03-18 | — | — | EP | disclosed |
| US-9671397-B2 | Method for functionalizing surfaces for analyte detection | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2017-06-06 | — | — | US | disclosed |
| US-9671397-B2 | Method for functionalizing surfaces for analyte detection | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2017-06-06 | — | — | US | disclosed |
| US-9671397-B2 | Method for functionalizing surfaces for analyte detection | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2017-06-06 | — | — | US | disclosed |
| US-20130203629-A1 | METHOD FOR FUNCTIONALIZING SURFACES FOR ANALYTE DETECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-08-08 | — | — | US | disclosed |
| US-20130203629-A1 | METHOD FOR FUNCTIONALIZING SURFACES FOR ANALYTE DETECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-08-08 | — | — | US | disclosed |
| US-20130172330-A1 | Chemokine Receptor Modulators | ALTIRIS THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130172330-A1 | Chemokine Receptor Modulators | ALTIRIS THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-8338448-B2 | Chemokine receptor modulators | ALTIRIS THERAPEUTICS, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-8338448-B2 | Chemokine receptor modulators | ALTIRIS THERAPEUTICS, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| WO-2012052874-A1 | METHOD FOR FUNCTIONALISING SURFACES FOR ANALYTE DETECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-04-26 | — | — | WO | disclosed |
| US-20100029634-A1 | Chemokine Receptor Modulators | ALTIRIS THERAPEUTICS, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029634-A1 | Chemokine Receptor Modulators | ALTIRIS THERAPEUTICS, INC. | 2010-02-04 | — | — | US | disclosed |
| WO-2009121063-A2 | CHEMOKINE RECEPTOR MODULATORS | ALTIRIS THERAPEUTICS (US) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172330-A1 | Chemokine Receptor Modulators | CCR5, CXCR4, ACKR3 | ALDH1A1 2030/4885TDP1 4048/4885L3MBTL1 4136/4885 |
| US-20220324770-A1 | NITRIFICATION INHIBITORS | NOS1, NOS2, NIT2 | ALDH1A1 1527/4885TDP1 1350/4885L3MBTL1 4645/4885 |
| US-20100029634-A1 | Chemokine Receptor Modulators | CCR5, CXCR4, ACKR3 | ALDH1A1 2030/4885TDP1 4048/4885L3MBTL1 4136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.